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ABSTRACT: Histone deacetylase 6 (HDAC6) and heat shock
protein 90 (Hsp90) are widely investigated anticancer drug targets.
Importantly, several lines of evidence indicate that their regulation
and activity are intimately linked, and that their combined
inhibition may lead to impressive therapeutic benefits. In this
study, we developed and applied an integrated computational
strategy to design dual inhibitors of HDAC6 and Hsp90. Although
the two targets share very little homology, an integrated ligand-
based and structure-based virtual screening approach indicated a
subset of compounds possessing the key structural requirements
for binding at both targets. In vitro tests demonstrated that some of
the selected candidates are able to selectively inhibit HDAC6 over
HDAC1, to increase the acetylation levels of tubulin on cell assays and to reduce cell proliferation. The discovered compounds
represent valuable starting points for further hit optimization.
■ INTRODUCTION
The molecular and genetic complexity of complex diseases
suggests that targeting a single oncogenic pathway may not be
sufficient to achieve durable remission in patients.1,2 As a
consequence, drug discovery efforts have been mainly focused
on targeting multiple signaling pathways, either via drug
combinations or through the development of a single
compound that is able to simultaneously hit multiple
oncogenic targets. Indeed, the design of drugs acting on a
single target has evolved into the concept of “polypharmacol-
ogy” or “multitarget” drug discovery, which aims at developing
a single drug that targets multiple biological systems
simultaneously.2
Histone deacetylase (HDAC) and heat shock protein 90
(Hsp90) enzymes are widely investigated anticancer drug
targets. The clinical relevance of HDAC inhibitors is testified
by the presence of four drugs approved by the U.S. Food and
Drug Administration, as well as by several drug candidates
currently under clinical evaluation for a variety of cancers.3 An
impressive number of Hsp90 inhibitors have been developed
to date, but none of them has received clinical approval
because of their low efficacy, toxicity, or de novo or acquired
drug resistance. Experience from clinical trials suggests that the
ability to reduce the dose without losing activity would be
clinically beneficial. Importantly, owing to the observed
beneficial synergistic effects, a number of clinical trials
including Hsp90 inhibitors in combination with other
anticancer drugs are currently ongoing.4 Importantly, Hsp90
and HDAC regulation and activity are intimately linked; their
inter-dependence and participation in overlapping signaling
networks in cancer cells making them ideal candidates for
multi-targeting approaches.5−11 In cancer cells, Hsp90 refolds,
stabilizes, and regulates the trafficking of many proteins
responsible for uncontrolled proliferation and apoptotic
resistance.12 Similarly, HDACs participate in the regulation
of many oncogenic processes. Although HDAC inhibitors have
demonstrated in vitro anticancer activity, clinical experience
with single-agent HDAC inhibitors has been variable,
suggesting that a combination of HDAC inhibitors with
other agents is warranted.13,14
Interestingly, recent studies have identified Hsp90 as a
substrate of histone deacetylase 6 (HDAC6).5−7 Although
HDACs are mainly involved in chromatin remodeling and
gene expression via direct modification of histones, HDAC6 is
responsible for the deacetylation and activation of several
cytosolic proteins, including Hsp90.5−7 Indeed, inactivation of
HDAC6 leads to the accumulation of acetylated Hsp90, which
is not able to form stable Hsp90−client complexes.15 In
addition, HDAC6 specifically deacetylates α-tubulin and
cortactin, two structural proteins involved in microtubule
dynamics and actin network, which are mechanisms involved
in cell division and migration.16 Therefore, the activity of
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HDAC6 heavily impacts on tumor cell invasion and metastasis.
Interestingly, several combinations of class I HDAC or
HDAC6 inhibitors with the first-in-class Hsp90 inhibitor 17-
AAG synergistically induced the degradation of numerous
Hsp90 client proteins in various cancer models.9,17−22
Moreover, impressive synergy has also been observed for the
NVP-AUY922 and NVP-HSP990 Hsp90 inhibitors with the
pan-HDAC inhibitor SAHA in multiple myeloma.23,24
Importantly, it was recently reported that administration of
HDAC inhibitors was able to resensitize resistant cells toward
the clinically relevant Hsp90 inhibitors 17-AAG and 17-
DMAG, and that resistant cells were also identified as cross-
resistant to structurally different Hsp90 inhibitors such as
radicicol and other second-generation Hsp90 inhibitors.25 Dual
inhibitors were recently reported.9,10 Altogether, these results
strongly support the rationale that a dual HDAC6/Hsp90
inhibitor may represent a suitable therapeutic strategy to
develop more effective anticancer drugs.
Based on the abovepresented evidence, we have developed
and applied a tailored strategy to design small molecular weight
dual inhibitors of Hsp90 and HDAC6 based on highly
integrated pharmacophores.
■ RESULTS AND DISCUSSION
The design of dual inhibitors of these targets is far from being
trivial because Hsp90 and HDAC6 belong to different protein
families and present a low sequence similarity (33%) and
sequence identity (17%), as evaluated by the EMBOSS Water
tool.26 Moreover, the two enzymes have different binding site
architectures and interact with structurally different substrates
in the cellular environment.27,28 Therefore, the design required
the application of a specially devised in silico procedure that
integrated different ligand- and structure-based approaches
(Figure 1). Experimental details on the computational
approaches are reported in the Experimental Methods section.
In particular, Hsp90 and HDAC6 inhibitors reported in
ChEMBL29 were analyzed, as described in the Experimental
Methods section to identify chemical “warheads,” that are able
to establish favorable interactions with known enzyme hot
spots, that is, Asp93 of Hsp90 and the catalytic zinc ion of
HDAC6. These analyses, performed by using in-house
developed tools based on OpenEye python toolkits,30 allowed
for the identification of eight (HDAC6) and eleven (Hsp90)
warheads (Figure 2), which were subsequently used to screen
the commercially available compounds of the ZINC database31
(www.zinc.docking.org., accessed on February 20, 2018).
Compounds in ZINC were first filtered to remove ligands
with unfavorable ADMET (absorption, distribution, metabo-
lism, excretion, and toxicity) properties, while preserving the
molecular diversity. Then, qualified compounds were sequen-
tially filtered for the presence of the identified Hsp90 and
HDAC warheads, leading to a focused library of purchasable
compounds possessing the warheads required to bind both
targets.
To evaluate which of the ligands in the filtered database
presented good 3D complementary with the Hsp90 and
HDAC6 binding sites, the compounds that passed the previous
filtering steps were docked into selected Hsp90 and HDAC6
crystal structures, using Glide.32 Considering that the use of
multiple crystallographic conformations helps accounting for
potential binding site flexibility issues and may improve
structure-based predictions,33,34 eleven Hsp90 and one
HDAC6 conformation, which are representative of the
conformational landscape of the two proteins, were selected
from the Protein Data Bank (PDB)35 (see Table S1 in the
Supporting Information). Moreover, Hsp90 crystal structures
Figure 1. Workflow for the design of Hsp90/HDAC6 dual inhibitors.
The devised workflow integrates different in silico approaches (i.e.,
data mining on publicly available databases to identify Hsp90 and
HDAC6 warheads, ligand- and structure-based virtual screenings on
commercial databases). The best candidates were tested by means of
in vitro assays on purified Hsp90, HDAC6, and HDAC1 (to check for
selectivity with respect to class I HDAC), as well as on cell lysates.
Figure 2. Hsp90 and HDAC6 warheads identified from the ligand-
based analyses made on ChEMBL.
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were prioritized according to the similarity of the screened
ligands with the co-crystallized ones, as this approach has
demonstrated to provide improved docking predictions.34,36
Visual inspection of the predicted poses and analysis of the
docking scores led to the selection of 10 compounds (Table 1)
to be tested in vitro. Interestingly, the best candidates included
compounds bearing the 5-(trifluoromethyl)-1,2,4-oxadiazole
chemical moiety previously reported in inhibitors selective for
HDAC6.37 Compounds based on this scaffold were of
particular interest to our aim, because the majority of the
reported HDAC inhibitors are not isoform selective, and pan-
inhibition of HDACs (e.g., by Vorinostat) is associated with
side effects.38,39 To confirm the in vitro inhibitory activities of
the selected candidate compounds, acetylation levels of tubulin
(HDAC6 target) and of histone H3 (HDAC6 off-target) were
evaluated in MCF7 cell-based assays (Figure 3, panel a).
After the induction of 24 h at a concentration of 50 μM,
compounds 1, 4, 5, 8, 9, and 10 were confirmed to reduce the
levels of ac-tubulin deacetylation, which depends on HDAC6,
with no or weak effect on deacetylation of the H3K9/14ac
histone, which depends on HDAC1 and other targets. These
data corroborate the percentages of HDAC6 and HDAC1
enzyme inhibition reported in Table 1. Selected compounds
were also used in MCF7 at a lower dose (5 μM), but in this
case, the acetylation of tubulin was found to be negligible,
suggesting that additional chemical modifications are necessary
to ameliorate their chemical/biological properties (e.g.,
compound stability and cell permeability). Moreover, to
evaluate whether, along with promising deacetylating/Hsp90
activities, selected compounds could impair cancer cell
proliferation, MTT assay was performed in MCF7 cells
(Figure 3, panel b). For 24 and 48 h of treatment, none of
the compounds proved to be toxic, although 5 and 8 were
shown to reduce breast cancer cell proliferation by about 50%.
Altogether, these results suggest that the compounds are likely
to exert in vitro antiproliferative effects through the
Table 1. Inhibitory Activity of the Selected Candidate Compounds of HDAC6, HDAC1, and Hsp90
aCompounds that showed the percentage of inhibition higher than 60% were further investigated at lower concentrations. bValues were measured
in triplicates. Percentages of inhibition are reported as mean ± SD. cPercentage of inhibition was evaluated at 1 μM. dValues were measured in
singlicate. Hsp90 assays were performed only for compounds that significantly reduced the deacetylation levels of tubulin, that is, compounds 1, 4,
5, 8, 9, and 10. eN.D.not determined. fN.A.not active, when the compound showed a percentage of inhibition lower than 10%.
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simultaneous modulation of multiple targets. According to the
predicted binding modes, the most active compound of the
series (compound 10 in Table 1 and Figure 4, panel a)
coordinates the zinc ion of the HDAC6 active site with the 5-
(trifluoromethyl)-1,2,4-oxadiazole chemical moiety, adopting a
conformation similar to that experimentally observed for other
HDAC inhibitors based on this scaffold.40 The phenyl ring
forms π−π stacking interactions with the Phe620 and Phe680
residues. Moreover, 2,4-diaminotriazine binds near His500,
Pro501, and Leu749, extending toward a solvent-exposed area
at the top of the HDAC6 cavity (residue numbering refers to
5EDU41). Interestingly, the latter chemical moiety was
predicted to form a hydrogen bond network with residues
Asp93, Wat2262, and Wat2137 of Hsp90 (Figure 4, panel b),
as previously observed for other Hsp90 inhibitors bearing the
2,4-diaminotriazine moiety42 (residue numbering refers to
1UY643). Finally, in Hsp90, the phenyl ring of 10 was
predicted to accommodate near residues Leu103, Leu107, and
Phe138, while the 5-(trifluoromethyl)-1,2,4-oxadiazole ring
extended toward a subpocket lined by residues Phe22, Gly108,
Trp162, and Phe170. Although 10 did not show high activity
toward Hsp90, the predicted binding modes provided useful
structural hints for further hit optimization. Moreover, ligand
similarity calculations on ChEMBL29 allowed for the
identification of a significant degree of similarity between the
selected compounds and known Hsp90 inhibitors (Table S2 in
the Supporting Information), supporting that higher Hsp90
activity could be obtained with proper structural modifications
of the identified scaffolds, which is currently ongoing.
■ CONCLUSIONS
In conclusion, a careful analysis of HDAC6 and Hsp90 ligands
reported in ChEMBL was first performed in order to identify
proper warheads of these two targets. Then, ligand-based and
structure-based screenings led to the selection of 10
compounds, which were evaluated for their activity on purified
enzymes and cell lysates.
Notably, HDAC6 and Hsp90 belong to different families
and possess very different binding sites, which makes the
design of dual inhibitors particularly challenging. Although the
identified compounds did not exhibit the desired balanced
Hsp90/HDAC6 dual activity, some of them were able to
selectively provide an increased level of acetylation of α-
tubulin, while showing no effects on histone H3 acetylation.
Moreover, two compounds also demonstrated the reduction of
breast cancer cell proliferation, according to the in vitro assays.
Interestingly, the identified scaffolds are small in size, which
Figure 3. HDAC in vitro assays. Panel (a): western blot analysis of acetylated histones and tubulin. Panel (b): MTT assay on MCF7 cells upon
compound exposure.
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makes them valuable starting points for further structure-based
optimization, which is currently ongoing.
■ EXPERIMENTAL METHODS
In Silico Analyses. Identification of Hsp90 and HDAC6
Chemical “Warheads”. Hsp90 and HDAC6 inhibitors, whose
activity annotations have been reported in terms of IC50, EC50,
Ki, or Kd, were first collected from the ChEMBL database
(accessed on February 20, 2018).29 Then, the activity records
were filtered to retain only those derived by binding
experiments on isolated proteins (assay confidence score
equal to or higher than 8), leading to the identification of 1342
and 2753 unique compounds for Hsp90 and HDAC6,
respectively. Afterward, the ligands were clustered by using
the Canvas Similarity and Clustering utility available in
Maestro.44,45 In particular, ligand similarity was assessed
through 32-bit linear path-based chemical fingerprints, which
encodes different atom types and bond orders and
discriminates aromatic from nonaromatic groups. Afterward,
hierarchical clustering was performed on the Tanimoto
similarity matrix that resulted from ligand-based similarities,
by using the “average” linkage method. A visual inspection of
ligands in the clusters allowed for a final selection of
compounds 11 and 8, from which representative substructures
(herein referred to as “warheads”) interacting with the
hotspots of Hsp90 (Asp93) and HDAC6 (Zn2+ ion) were,
respectively, extracted (see Figure 2).
Selection of Representative Crystal Structures of Hsp90
and HDAC6. Crystal structures of human Hsp90 and HDAC6
(catalytic domain II) proteins were first downloaded from the
PDB and split into their component chains (accessed on
January 30, 2018) leading to 271 and 2 complexes,
respectively. Then, the resulting complexes were preprocessed
with the Protein Preparation Wizard utility available in
Maestro (Schrödinger).44 In particular, atom types and bond
connectivity issues were fixed, hydrogen atoms were added,
and H-bond networks were optimized. Ions and water and
solvent molecules were also removed from the complexes,
except for water molecules establishing conserved H-bond
networks with the ligand and the residues of the Hsp90 protein
binding site.46 Afterward, the prepared crystal structures were
aligned by using the protein structure alignment tool available
in Maestro44 and manually clustered according to the spatial
arrangements of the binding site residues, leading to a set of 11
and 1 clusters of structurally diverse Hsp90 and HDAC6
conformations, respectively. Finally, one ligand−protein
complex was selected as a representative structure for each
cluster (see Table S1). Redocking calculations using Glide32,47
were subsequently performed on the representative crystal
complexes of Hsp90 and HDAC6 to validate the docking
models. Ligands extracted from the representative complexes
were prepared for the redocking calculations using the LigPrep
utility available in the Schrödinger suite.48 In particular, every
combination of ionization and tautomeric states potentially
present at pH equal to 7 ± 2 were evaluated. Moreover, as
HDAC6 contains a Zn ion in the active site, which is necessary
for the catalytic activity of the protein, additional metal-
binding states were also computed.
The prepared Hsp90 crystallographic ligands were finally
redocked into the selected representative HDAC6 and Hsp90
enzymes. Default settings of the Standard Precision protocol
were used to perform docking calculations, and receptor grids
were centered at the centroids of the co-crystallized ligands.
The ability of the models to reproduce the crystallographic
poses of the ligands was evaluated in terms of rmsd, which
always resulted to be lower than 2.0 Å (Table S1). Moreover, a
visual inspection of the docking complexes was also carried out
to better evaluate the protein−ligand interactions established
in the predicted docking poses.
Virtual Screening. The ZINC31 database (release 15,
containing ∼735 mL of purchasable compounds; accessed on
February 20, 2018) was first downloaded and filtered using
FILTER49,50 software of the OpenEye suite. In particular,
ligands with molecular weights ≤200 and ≥650 and predicted
poor ADMET properties were removed. Then, the screening
compounds were sequentially filtered on the identified
HDAC6 and Hsp90 chemical warheads (see Figure 2),
which are important for binding to the two proteins.
Substructure filtering was performed by using an in-house
developed script implemented with OpenEye python tool-
kits.30 Afterward, compounds that passed the previous stages of
filtering were prepared for docking calculations by using
LigPrep with the same modalities described above. All
combinations of stereoisomers were also generated for
molecules with undefined stereocenters, at this stage of ligand
preparation.
Docking calculations of the screening ligands were finally
performed on Hsp90 and HDAC6 crystal structures, selected
according to the similarity between the screened and co-
crystallized ligands. In particular, HDAC6 and Hsp90 ligands
were first extracted in their bound conformation from the
prepared crystal structures and grouped according to the
cluster membership of their parent protein conformations.
Then, screening compounds were docked into the Hsp90 and
HDAC6 representative crystal structures, whose cluster-based
Figure 4. Predicted docking poses of 10 in HDAC6 and Hsp90
binding sites. In particular, panels (a,b) report the predicted binding
modes of compound 10 in the 5EDU (HDAC6) and 1UY6 (Hsp90)
crystal structures, respectively.
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crystallographic ligands provided the highest similarity
according to the ECFP4 and MACCS fingerprints.51,52 A
visual inspection of the predicted binding modes and an
analysis of the scores led to a selection of 10 candidate
compounds to be tested in vitro on Hsp90- and HDAC6-
purified proteins and on cell-based assays.
Ligand-based Similarity Calculations on ChEMBL. To
evaluate whether the identified compounds present a high
degree of structural similarity with respect to Hsp90 inhibitors
reported in the literature, 2D similarity analyses were also
carried out. In particular, Hsp90 inhibitors were first
downloaded from the ChEMBL database and filtered to retain
only those with activity annotations derived by binding
experiments on isolated proteins (ChEMBL assay confidence
score equal to or greater than 8), and expressed as IC50, EC50,
KI, or Kd. Then, 2D similarity analyses were performed by
using the MACCS and ECFP4 fingerprints’ implemented
OpenEye python toolkits.30,51,52 These types of fingerprints
were selected for the similarity estimations among those
available, as they take into account different structural aspects
of ligand similarity. The 2D fingerprint analyses revealed a
notable degree of similarity between the identified molecules
(i.e., 4, 5, 8, 9, and 10) and several Hsp90 ligands reported on
ChEMBL (see Table S2). Interestingly, the majority of the
identified similarity records resulted from the ECFP4fp-based
calculations, with the evaluated scores being always higher than
activity-relevant thresholds of similarity.53
Experimental Assays. Cell Line. The breast cancer cell
line MCF7 (ATCC) was grown in DMEM medium (Euro-
clone, Milan, Italy) with 10% fetal bovine serum (Euroclone),
2 mM L-glutamine (Euroclone), and antibiotics (100 U/mL
penicillin, 100 L g/mL streptomycin) (Euroclone). Cells were
stimulated with drugs for indicated times at 5 and 50 μM.
Western Blot Analysis. To quantify the acetylation levels,
we performed the total protein and histone extraction by
evaluation of the acetylation effects of Ac-tubulin, as the target
of HDAC6, and of histone H3K9,14ac, as the off-target.
Total Protein Extraction. After the induction with epidrugs
at the indicated times and concentrations, MCF7 cells were
then harvested, washed with phosphate-buffered saline (PBS)
(Euroclone), and lysed for 15 min at 4 °C in a lysis extraction
buffer with protease and phosphatase inhibitors (50 mM Tris−
HCl of pH 8.0, 150 mM NaCl, 1% NP40, 10 mM sodium
fluoride, 0.1 mM sodium orthovanadate, 40 mg/mL phenyl-
methylsulfonyl fluoride (PMSF), 20 g/mL aprotinin, 20 mg/
mL leupeptin, 2 mg/mL antipain, 10 mM p-nitrophenyl
phosphate, 10 mg/mL pepstatin A, and 20 nM okadaic acid).
Cells were vortexed, then centrifuged at 13,000 rpm for 30 min
at 4 °C. The protein concentration was determined by a
colorimetric assay (Biorad, Italy). Cell extracts were 1:1 diluted
in the 2× Laemmli sample buffer (0.217 M Tris−HCl with pH
8.0, 52.17% SDS, 17.4% glycerol, 0.026% bromophenol blue,
and 8.7% β-mercaptoethanol), and then boiled for 3 min.
Equal amounts of protein (50 μg) were run, separated by
SDS−PAGE gel, transferred onto nitrocellulose membranes,
and incubated with primary antibodies. Primary antibodies
used were acetyl-tubulin (Sigma) and anti-GAPDH antibody
(Santa Cruz Biotechnology) for loading control. The immune
complexes were first detected with horseradish peroxidase-
conjugated species-specific secondary antiserum (Bio-Rad
Laboratories, Milan, Italy), and then by an enhanced
chemiluminescence reaction (Bio-Rad Laboratories, Milan,
Italy). Densitometric analysis of protein expression was
performed by using the ImageJ image processing package.
Histone Extraction. After the induction with epidrugs at the
indicated times and concentrations, MCF7 cells were harvested
and washed twice with cold 1× PBS and lysed in Triton
extraction buffer (TEB; PBS containing 0.5% Triton X 100 (v/
v), 2 mM PMSF, and 0.02% (w/v) NaN3) for 10 min on ice,
with gentle stirring. After centrifugation (2000 rpm at 4 °C for
10 min), the supernatant was removed, and the pellet was
washed in half the volume of TEB and centrifuged as before.
The pellet was overnight incubated in 0.2 N HCl at 4 °C on a
rolling table. The samples were then centrifuged at 2000 rpm
for 10 min at 4 °C; the concentration of protein in the
supernatant was determined using a Bradford assay (Bio-Rad,
CA, USA). For the detection of histone H3 acetylation,
H3K9,14ac (Diagenode) was used. Histone H4 (Abcam)
antibodies and Pounceau Red (Sigma) were used to normalize
for equal loading. Semi-quantitative analysis was performed
using ImageJ software.
Cell Viability Assay. MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] (Sigma-Aldrich, Milan,
Italy) assay was used to determine the proliferation of
MCF7 cells after treatment with epidrugs at indicated
concentrations. 7 × 104 cells/well were plated in a 24-well
plate and treated, in triplicates, with compounds at 50 and 5 μg
for 24 and 48 hours of induction. After treatment, MTT
solution was added for 3 h at 0.5 mg/mL, the purple formazan
crystals were dissolved in dimethyl sulfoxide (Sigma-Aldrich,
Milan, Italy), and the absorbance was read at a wavelength of
570 nm using a TECAN M-200 reader.
Fluorimetric HDAC Assays. HDAC1 and HDAC6 recombi-
nant enzymes (10 ng per reaction; BPS Bioscience Catalog #:
50051 and 50006, respectively) were incubated in the HDAC
buffer (50 mM Tris−HCl of pH 8.0, 137 mM NaCl, 2.7 mM
KCl, and 1 mM MgCl2) with specific substrates (50 μM) and
epidrugs, at concentration of 5 and 50 μM. As a HDAC1
substrate, the derivative of fluorescent tert-butyloxycarbonyl
(Boc)-(Ac)-Lys-7-amino-4-methylcoumarin (AMC), called
MAL, the benzyloxycarbonyl analogue Z-MAL was used. For
HDAC6, the substrate was instead an (S)-[5-acetylamino-1-(2-
oxo-4-trifluoromethyl-2H-chromen-7-ylcarbamoyl)pentyl]-
carbamic acid tert-butyl ester. Reactions were carried out for 1
h at 37 °C in black microplates (Corning Costar, cod: 266).
Deacetylation sensitizes the substrate to the developer step
[trypsin 6 mg/mL in trypsin buffer (50 mM Tris−HCl of pH
8.0 and 100 mM NaCl)], and it is directly proportional to the
produced fluorophore. The fluorophore is excited with a 360
nm light, and the emitted light (460 nm) has been quantified
with a TECAN Infinite M200 station. SAHA (5 μM) was used
as the deacetylation control for HDAC1 assay and Tubastatin
(5 μM) for HDAC6.
HSP90 Assay. Compounds that reduced the levels of ac-
tubulin deacetylation, that is, 1, 4, 5, 8, 9, and 10 have also
been tested in vitro to evaluate their Hsp90α inhibitory
activity, in singlicate. The employed Hsp90α assay kit is
designed for the identification of Hsp90α inhibitors using
fluorescence polarization. The assay is a competitive binding
assay, based on the binding of fluorescently labeled
geldanamycin, an HSP90 inhibitor, to purified recombinant
Hsp90α. The assay was carried out as suggested by the
manufacturer (Hsp90α N-Terminal Domain Assay Kit, BPS
Bioscience Catalog #50293). Epidrugs were used at the
concentrations of 50 and 5 μM. 17-AAG (KOS953, APExBIO
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Catalog #: A4054) was used as a reference compound.
Fluorescent polarizations of samples were performed at the
intervals of 475−495 nm (excitation) and 518−538 nm
(emission) in low-binding black microplates (Corning Costar,
cod: 266).
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